• Linoleic Acid: Assay Setup and QC Guide

  2026-09-09

  This practical guide explains how to use Linoleic Acid (SKU C3108) in oxidative stress, erythrocyte, epithelial migration, membrane, and nutritional deficiency workflows. It is suitable for freshly prepared solvent stocks and controlled in vitro or animal-study designs, but not for aqueous stock preparation or long-term storage of solutions.

• From Barrier Biology to Faster Genotyping

  2026-09-09

  Mechanistic studies of intestinal barrier protection are only as reliable as the models and genotyping workflows behind them. This thought-leadership article connects the NR1I3–E-cadherin findings in DSS-induced colitis with practical, contamination-conscious DNA preparation using K1026.

• KIR2.1 Inhibition in Pulmonary Vascular Remodeling

  2026-09-08

  The study by Cao and colleagues links KIR2.1 activity with pulmonary artery smooth muscle cell proliferation and migration through the TGF-β1/SMAD2/3 pathway. Its combined rat-model and human-cell experiments provide a mechanistic rationale for studying Kir2.1 in pulmonary vascular remodeling, while also highlighting the need for further validation beyond pharmacological inhibition.

• CENPI Drives Breast Cancer via Wnt/β-Catenin

  2026-09-08

  Wu et al. identify centromere protein I (CENPI) as an overexpressed breast cancer driver and connect its activity to Wnt/β-catenin signaling. By combining patient datasets, tissue staining, cellular assays, xenografts, RNA sequencing, and pathway reporters, the study provides a mechanistic framework for evaluating CENPI as a biomarker and potential therapeutic target.

• CUDC-907 In Vitro Protocol and QC Guide

  2026-09-07

  CUDC-907 (SKU A4097) is a dual PI3K and HDAC inhibitor for controlled in vitro studies of PI3K/AKT signaling, histone acetylation, cell-cycle progression, and apoptosis. This guide translates the product dossier into practical assay setup and QC steps; the reagent is for scientific research only and not for diagnostic, therapeutic, or clinical use.

• Gamma-linolenic acid (GLA) Research Workflows

  2026-09-07

  Build reproducible GLA experiments around receptor binding, inflammatory signaling, viability, and apoptosis rather than relying on a single endpoint. This workflow also shows how surveillance principles from antibacterial-resistance research can improve assay design without overstating what the evidence proves.

• Neurotensin: GPCR Trafficking Workflow

  2026-09-05

  Build a controlled Neurotensin workflow that separates rapid G protein-coupled receptor signaling from slower miR-133α and receptor-recycling outcomes. This guide combines practical dosing, sample handling, fluorescence-interference controls, and troubleshooting for gastrointestinal and cellular trafficking studies.

• Pyridostatin TFA: A Structure-First Research Guide

  2026-09-04

  Pyridostatin TFA is a powerful probe for studying G-quadruplex stabilization, telomere dysfunction, and structure-dependent cell responses. This guide connects established DNA applications with emerging RNA G-quadruplex and TDP-43 assays while emphasizing controls, interpretation, and experimental maturity.

• Tofacitinib Citrate: Beyond JAK3 Selectivity

  2026-09-04

  Tofacitinib citrate is more than a JAK3-focused tool for lymphocyte biology. Its value in translational research emerges when immune signaling, concentration, endothelial responses, and assay context are interpreted together. This article connects CP-690550 citrate with vascular inflammation research and provides a practical framework for designing more decision-ready experiments.

• Nitroaromatic Nannocystin Targets AKT1 in Colorectal Cancer

  2026-09-03

  The reference study identifies a nitroaromatic nannocystin, compound 4, as a nanomolar inhibitor of colorectal cancer models and links its activity to AKT1 using transcriptomics, molecular docking, and cellular thermal shift analysis. Its activity across cell lines, patient-derived organoids, and a patient-derived xenograft model provides a useful preclinical framework for evaluating macrocyclic targeted agents.

• Ceftolozane Sulfate: From Target to Translation

  2026-09-03

  A thought-leadership guide for translating Ceftolozane sulfate from PBP-directed cell-wall inhibition into susceptibility, resistance, and PK/PD study design for resistant Pseudomonas aeruginosa.

• Verteporfin A8327: Reliable Cell Assays

  2026-09-02

  A scenario-based guide to using Verteporfin (SKU A8327) in viability, apoptosis, proliferation, and autophagy experiments. It explains light-dependent cytotoxicity, light-independent pathway effects, formulation controls, protocol parameters, and practical product-selection criteria for reproducible laboratory workflows.

• CENPI Drives Breast Cancer via Wnt/β-Catenin

  2026-09-02

  Wu and colleagues identify centromere protein I (CENPI) as an overexpressed breast cancer driver associated with disease progression and poor prognosis. By combining patient-data analysis, cellular assays, xenograft models, RNA sequencing, and Wnt/β-catenin reporter validation, the study connects a chromosome-segregation protein to a major oncogenic signaling pathway and suggests a biomarker and therapeutic research direction.

• 10074-G5: A Mechanism-First c-Myc Inhibitor Guide

  2026-09-01

  Explore how 10074-G5, a c-Myc inhibitor, can be used to interrogate MYC-driven phenotypes without confusing pathway correlation with direct target engagement. This mechanism-first guide connects the MYC/TERT/NFκB axis to assay selection, controls, and translational interpretation.

• ZIF-8 Nanotheranostics for Ultrasound-Guided TNBC Therapy

  2026-09-01

  Li et al. developed a folic acid–PEG-functionalized ZIF-8 nanoplatform that delivers ciprofloxacin while supporting ultrasound imaging, sonodynamic therapy, chemotherapy, and immune activation. In triple-negative breast cancer models, ultrasound-triggered ROS generation and immunogenic cell death were associated with stronger tumor control and increased CD8+ T-cell infiltration.

8036 records 1/536 page Next 12345 下5页 Last page